First Choice Neurology

First Florida Patient to Receive Biogen Aducanumab Infusion

Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly infusion treatment for early-stage Alzheimer’s patients. The drug works to decrease amyloid plaque in the brain, which is a marker for Alzheimer’s disease. According to Dr. …

First Florida Patient to Receive Biogen Aducanumab Infusion Read More »

Notable COVID-19 Variants in the United States

According to the CDC, currently, there are four notable COVID-19 variants in the United States: B.1.1.7 (Alpha): This variant was first detected in the United States in December 2020. It was initially detected in the United Kingdom. B.1.351 (Beta): This variant was first detected in the United States at the end of January 2021. It …

Notable COVID-19 Variants in the United States Read More »

What do Scientists Know about the Delta Variant?

The COVID-19 Delta variant is extremely contagious and responsible for about 1 in 5 COVID-19 cases in the United States, and cases have doubled in the last two weeks, according to health officials. The US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) are very concerned about the Delta variant. …

What do Scientists Know about the Delta Variant? Read More »

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s

In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause dementia. For example, amyloid and tau proteins build up in Alzheimer’s disease, and their levels can be measured in CSF. These abnormalities contribute to the …

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s Read More »

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders

Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the specific daily impact of dementia on my patients and allows me to implement a meaningful treatment plan. This plan can include medication as well as …

Medicare Sees a Growing Demand for Cognitive Assessment with Patients Suffering from Memory Disorders Read More »

FDA Approves Promising Alzheimer’s Treatment

Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA to approve Biogen’s Aducanumab, a promising infusion treatment for Alzheimer’s patients. Dr. Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, …

FDA Approves Promising Alzheimer’s Treatment Read More »

Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study

Last week Sage Therapeutics, Inc. and Biogen Inc. announced the results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor. Essential Tremor (ET) is a movement disorder affecting an estimated 6.4 million Americans. For ET patients, uncontrollable shaking of the hands, head, voice, or legs creates difficulty eating, …

Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study Read More »

Parkinson’s Disease Awareness Month

Did you know that April is Parkinson’s disease (PD) Awareness Month? Every April, doctors, patients, families, hospitals, and foundations raise awareness about Parkinson’s disease. Test your knowledge of Parkinson’s disease during Parkinson’s Awareness Month. Do you think you know a lot about Parkinson’s? Take the PD quiz to see how much you know! There are …

Parkinson’s Disease Awareness Month Read More »

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon

Eli Lilly’s clinical trial of the experimental drug donanemab appears to have successfully slowed cognitive decline in patients with the early symptoms of Alzheimer’s. The TRAILBLAZER-ALZ clinical trial was a relatively small, placebo-controlled, double-blind, multi-center Phase 2 study measuring the safety, tolerability, and efficacy of donanemab in patients with early symptomatic Alzheimer’s. Clinical Trial Results …

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon Read More »

COVID-19 Long-Haulers Facebook Live Series

Do you suffer from post-COVID-19 syndrome, also referred to as COVID-19 Long-Haulers? Symptoms may include fatigue, shortness of breath, headaches, dizziness, trouble sleeping, and brain fog, or difficulty thinking clearly. Thousands of Americans who had a mild case of COVID-19 are battling a wide range of health problems. Evidence shows that at least one-third of …

COVID-19 Long-Haulers Facebook Live Series Read More »

Translate »